|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.68 USD | +0.98% |
|
-1.28% | -17.69% |
| Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
| Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
Incyte Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 3,695.65 million compared to USD 3,394.64 million a year ago. Net income was USD 597.6 million compared to USD 340.66 million a year ago.
Basic earnings per share from continuing operations was USD 2.67 compared to USD 1.53 a year ago. Diluted earnings per share from continuing operations was USD 2.65 compared to USD 1.52 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -17.69% | 11.6B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B | |
| +2.29% | 7.72B |
INCYTE CORPORATION 
